Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Crescent Biopharma (CBIO) Leases (2020 - 2026)

Crescent Biopharma (CBIO) has disclosed Leases for 7 consecutive years, with $1.4 million as the latest value for Q1 2026.

  • For Q1 2026, Leases changed N/A year-over-year to $1.4 million; the TTM value through Mar 2026 reached $1.4 million, changed N/A, while the annual FY2025 figure was $1.5 million, N/A changed from the prior year.
  • Leases hit $1.4 million in Q1 2026 for Crescent Biopharma, down from $1.5 million in the prior quarter.
  • Across five years, Leases topped out at $1.6 million in Q2 2025 and bottomed at $424209.0 in Q2 2024.
  • Average Leases over 5 years is $1.1 million, with a median of $1.1 million recorded in 2022.
  • Year-over-year, Leases crashed 64.13% in 2024 and then skyrocketed 277.17% in 2025.
  • Crescent Biopharma's Leases stood at $751174.0 in 2022, then increased by 2.22% to $767828.0 in 2023, then crashed by 44.75% to $424209.0 in 2024, then skyrocketed by 246.29% to $1.5 million in 2025, then decreased by 6.6% to $1.4 million in 2026.
  • According to Business Quant data, Leases over the past three periods came in at $1.4 million, $1.5 million, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.